Objective The aim of this study was to investigate the responses of serum osteocalcin (OC), undercarboxylated osteocalcin (ucOC) 
Introduction

Vitamin K is a cofactor of γ-carboxylase that mediates the conversion of undercarboxylated osteocalcin (ucOC) to osteocalcin (OC) by transforming glutamyl (Glu) residues of OC to γ-carboxyglutamic acid (Gla) (1, 2). Recent in vivo and in vitro studies showed that vitamin K and its analogues have a therapeutic effect on bone metabolism. In particular, menatetrenone, vitamin K2 with four isoprene units, has ment of corticosteroid-induced osteoporosis, and recommended vitamin K2 as a second-line therapy to be used in combination with bisphosphonates as the first-line therapy (11). However, there have been few attempts to evaluate the effect of vitamin K2 on bone metabolism in corticosteroid-treated patients.
In the present study, we performed serial measurements of serum bone metabolic markers such as OC, ucOC (Fig. 1 ). There were no significant differences between the two groups at all time points throughout the entire observation period. (Fig. 3) .
Patients and Methods
Patients
Between March 2004 and September 2007, we enrolled 23 patients for a long-term observation study and 6 patients for a short-term observation study at Sapporo Medical University Hospital. This study was approved by the local ethical committee, and written informed consent was obtained from all participants.
Long-term observation
Results
Baseline characteristics
T a b l e 1 . Ch a r a c t e r i s t i c s o f t h e P a t i e n t s a t B a s e l i n e
F i g u r e 1 . Or a l p r e d n i s o l o n e d o s e a f t e r s t a r t i n g r i s e d r o n a t e mo n o t h e r a p y ( g r o u p A; c l o s e d c i r c l e s ) o r c o mb i n e d r i s ed r o n a t e a n d v i t a mi n K2 t h e r a p y ( g r o u p B ; o p e n c i r c l e s ) . Da t a a r e me a n ± S E . B e t we e n -g r o u p a n a l y s i s s h o we d n o s i g n i f i c a n t d i f f e r e n c e s a t a l l t i me p o i n t s a l t h o u g h t h e me a n v a l u e s we r e r e l a t i v e l y h i g h i n g r o u p A u p t o 3 mo n t h s .
F i g u r e 2 . P e r c e n t c h a n g e s o f s e r u m o s t e o c a l c i n ( OC) l e v e l a f t e r s t a r t i n g r i s e d r o n a t e mo n o t h e r a p y ( g r o u p A; c l o s e d c i r c l e s ) o r c o mb i n e d r i s e d r o n a t e a n d v i t a mi n K2 t h e r a p y ( g r o u p B ; o p e n c i r c l e s ) . Da t a a r e me a n ± S E . T h e a s t e r i s k s i n d i c a t e s i g n i f i c a n t d i f f e r e n c e s c o mp a r e d wi t h b a s e l i n e ( p < 0 . 0 5 ) .
markers, because corticosteroids, even prednisolone at the low-dose of 5 mg/day, could suppress bone metabolic markers as rapidly as within 2 weeks (13).
Changes of prednisolone dose in the long-term observation
Changes of BMD in the long-term observation
A significant decrease of OC persisted until 12 months in both groups (Fig. 2) . On the other hand, the significant change of ucOC disappeared at 12 months in group A, although a significant decrease below -60% persisted throughout the entire course of study in group B (Fig. 3) .
The percent changes of ucOC/OC ratio at 1 week, 1 (Fig. 4) . Analyses of the time course of mean changes of the two groups detected no significant difference between the groups at all time points throughout the entire observation period.
F i g u r e 3 . P e r c e n t c h a n g e s o f s e r u m u n d e r c a r b o x y l a t e d o s t e o c a l c i n ( u c OC) l e v e l a f t e r s t a r t i n g r i s e d r o n a t e mo n o t h e r a p y ( g r o u p A; c l o s e d c i r c l e s ) o r c o mb i n e d r i s e d r o n a t e a n d v i t a mi n K2 t h e r a p y ( g r o u p B ; o p e n c i r c l e s ) . Da t a a r e me a n ± S E . T h e a s t e r i s k s i n d i c a t e s i g n i f i c a n t d i f f e r e n c e s c o mp a r e d wi t h t h e b a s e l i n e ( p < 0 . 0 5 ) .
F i g u r e 4 . P e r c e n t c h a n g e s o f t h e u c OC/ OC r a t i o a f t e r s t a r t i n g r i s e d r o n a t e mo n o t h e r a p y ( g r o u p A; c l o s e d c i r c l e s ) o r c o mb i n e d r i s e d r o n a t e a n d v i t a mi n K2 t h e r a p y ( g r o u p B ; o p e n c i r c l e s ) . Da t a a r e me a n ± S E .
F i g u r e 5 . P e r c e n t c h a n g e s o f s e r u m t y p e I c o l l a g e n c r o s sl i n k e d N-t e l o p e p t i d e ( NT x ) l e v e l a f t e r s t a r t i n g r i s e d r o n a t e mo n o t h e r a p y ( g r o u p A; c l o s e d c i r c l e s ) o r c o mb i n e d r i s ed r o n a t e a n d v i t a mi n K2 t h e r a p y ( g r o u p B ; o p e n c i r c l e s ) . Da t a a r e me a n ± S E . T h e a s t e r i s k s i n d i c a t e s i g n i f i c a n t d i f f e r e n c e s c o mp a r e d wi t h b a s e l i n e ( p < 0 . 0 5 ) .
F i g u r e 6 . T h e e f f e c t o f i n t r a v e n o u s s t e r o i d p u l s e t h e r a p y o n p e r c e n t c h a n g e s i n s e r u m o s t e o c a l c i n ( OC; c l o s e d c i r c l e ) , u n d e r c a r b o x y l a t e d o s t e o c a l c i n ( u c OC; o p e n c i r c l e ) a n d t y p e I c o l l a g e n c r o s s -l i n k e d N-t e l o p e p t i d e ( NT x ; g r a y c i r c l e ) l e v e l s . Da t a a r e me a n ± S E . T h e a s t e r i s k s i n d i c a t e s i g n i f i c a n t d i f f e r e n c e s c o mp a r e d wi t h b a s e l i n e ( p < 0 . 0 5 ) .
Changes of NTx in the long-term observation
The percent changes from baseline at 1 week, 1 month, 3 months and 12 months were -24. 6±7.1, -28.2±9.1, - (Fig. 5) .
Changes of bone metabolic markers in the shortterm observation
Steroid pulse therapy led to significant changes in OC (-47 (Fig. 6) . On the other hand, there were no significant changes in NTx from the baseline after 1 week (-2.9±17.8%) and 1 month (-9.7± 13.2%).
Discussion
Osteoclacin is one of the most abundant noncollagenous proteins produced by osteoblasts in bone matrix (14, 15) . Since a part of the OC enters the bloodstream, the serum OC concentration is used as a marker of bone forma-tion (16, 17 (18) (19) (20) (21) and that a high serum concentration of ucOC is related to the risk of fracture in elderly women or osteoporotic patients (22) (23) (24) (25) (26) Another striking finding in this study is that serum concentrations of OC and ucOC follow a very similar time course (27) . The precise turnover of OC and ucOC in human serum has not been reported in the literature, although a study in rat models reported that one-half of the administered bone Gla protein may be cleared from serum in less than 5 minutes (17) . Various studies have demonstrated that corticosteroids depress bone formation with a decrease in osteoblastic activity that is generally attributed to the direct inhibitory effect of corticosteroids on bone formation (28) (29) (30) . This would explain the significant decrease in OC during corticosteroid therapy as was also reported previously (12) (4, 31) . In the long-term observation, the mean ucOC/OC ratios up to 3 months were relatively lower in group A than in group B in spite of combined therapy with vitamin K2 in group B (Fig. 4) . This paradoxical result may be explained by the relatively high dose of prednisolone used in group A compared with group B, although the dose difference did not reach a statistical significance (Fig. 1) Consistent with a previous report (32) , the present study also showed that risedronate significantly reduced NTx in corticosteroid-treated patients, and the magnitude of reduction observed was similar to that previously reported in osteoporotic patients (33, 34) . Since NTx has been used as a bone resorption marker in several reports (35, 36) , our result suggests that risedronate can induce a significant reduction of bone turnover against the increased osteoclast-mediated bone resorption induced by corticosteroids (37) . Although past studies have shown that vitamin K2 exhibits two contradictory functions; activation (38) and inhibition (39, 40) 
